SB 239063, , >98% (HPLC)
Application
SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.
Biochem/physiol Actions
Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
Packaging
5, 25 mg in glass bottle
| Colour | white |
|---|---|
| Quality Level | 100 |
| mp | 206-207.2 °C |
| InChI key | ZQUSFAUAYSEREK-WKILWMFISA-N |
| InChI | 1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16- |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | >98% (HPLC) |
There are no downloads for this product.
